21
Organized by November 7– 8, 2019 Renaissance Hotel, Washington, DC THE ONLY COMMERCIALLY FOCUSED AMR CONFERENCE GLOBALLY www.terrapinn.com/antimicrobial FEATURING
Organized by
November 7– 8, 2019Renaissance Hotel, Washington, DC
THE ONLY COMMERCIALLY FOCUSED AMR CONFERENCE GLOBALLY
www.terrapinn.com/antimicrobial
FEATURING
Since 2015, the World Anti-Microbial Resistance Congress has been the only commercially focused conference globally of its kind.
Launched during the release of key reports such as the AMR Review and A Scientific Roadmap for Antibiotic Discovery, the World AMR Congress has brought attention to the threats of this emerging crisis to the global healthcare system.
The conference gathers global leaders in infectious diseases to meet, brainstorm and discuss the challenges and opportunities on seven topic areas:
• Antibiotic R&D: advancing the development of antibiotic and non-traditional therapies and improving commercialization strategies
• Diagnostics: innovating the development and deployment of rapid diagnostics tests, while ensuring an effective integration into hospitals’ workflow and reimbursement
• Antimicrobial stewardship: using technology to improve antibiotic prescription, monitoring and surveillance while advancing stewardship-based purchasing guidelines
• Pitch & Partner: joining funding and partnerships with antibiotics and diagnostics innovation
• Infection Control: advancing policies to improve infection prevention, control and compliance in healthcare facilities
• Manufacturing: overcoming challenges for a sustainable and controlled antibiotic manufacturing and supply chain
• Vaccines: discussing the clinical and economic value of vaccines to combat AMR
This November 7-8, 2019, 600 attendees from over 40 countries will be gathered at the Renaissance Washington, D.C. Downtown Hotel for the largest AMR conference ever.
We look forward to meeting you in D.C.
OUR STORY
Register now at www.terrapinn.com/antimicrobial
André SingerGeneral Manager – Life SciencesT/ +1 646 619 1797 E/ [email protected] Jonathan
Van-TamDeputy Chief Medical Officer UK Department of Health
KEYNOTE ADDRESS: UK’s efforts to combat resistance and create a sustainable commercial environment for existing and future antibiotics
FACTS & FIGURESANTIMICROBIAL RESISTANCE STATS – WHY WE NEED TO TAKE ACTION
By 2050, it is believed that superbugs will kill up to 10 million people each year*
2050
people die each year thanks to antimicrobial resistance globally, **
700,000 people in the U.S. get an antibiotic-resistant infection, and at least 23,000 people die from it**
2 MILLION
By contrast, 19 new antimicrobial drugs were approved between 1980 and 1984.
19
new antimicrobial drugs were approved, most of them additions to existing drug classes, according to the World Health Organization.
ONLY 6of common human infections are already resistant to currently available medicines in some high-income countries.
35%
for some antibiotic-bacterium combinations In some low- and middle-income countries (LMICs).***
80-90% resistance rates are as high as
Between 2010–2014
* WHO’s Report No Time to Wait: Securing the future from drug-resistant infections** CDC’s Report Antibiotic Resistance Threats in the United States, 2013 *** OCDE’s Report Stemming the superbug tide: Just a few dollars more. November 7, 2018.
Jeremy Knox, Director of Policy, Drug Resistant Infections, Wellcome Trust
Evan Loh, Chairman, Antimicrobials Working Group, President, Chief Operating Officer, Chief Medical Officer, Paratek Pharmaceuticals
Melissa Stundick, Executive Director, Strategic Alliances, Spero Therapeutics
Aleks Engel, Director, REPAIR Impact Fund, Novo Holdings
Kevin Outterson, Professor, Boston University, Executive Director, CARB-X
Amanda Jezek, Senior Vice President, Public Policy and Government Relations, Infectious Diseases Society of America
KEYNOTE PANEL: ANALYZING THE POTENTIAL IMPACT OF CURRENT COMMERCIAL AND ‘PULL’ INITIATIVES
ANTIBIOTIC DEVELOPMENT
This track covers everything from discovery through to commercialization and payment reform. Learn about the latest innovative pre-clinical, clinical, commercial pathways, and best practices in traditional and non-traditional antibiotic development. Dive into conversations on “pull” incentives with industry leaders, heads of commercial development and policymakers.
MARINA KOZAK
Biologist, Division of CBRN Countermeasures
PAMELA TENAERTSExecutive Director
COLM LEONARD
Clinical Advisor
CHRISTINE ÅRDAL
Senior Advisor, EU-JAMRAI
MARK ALBRECHT
Chief (Acting), Antibacterials Program
SARANSH CHAUDHARYChief Executive Officer
SHEILA CONNELLY
Vice President of Research
MICHAEL P. BEVILACQUAChief Executive Officer
CARA CASSINOChief Medical Officer and
Executive Vice President of Research and Development
JENNY HELLMAN
Analyst
MONIKA SCHNEIDER
Research Associate
PETER BEYERSenior Advisor
DAVID ROBLINChief Operating Officer, Chief
Medical Officer, President of R&D
GUY MACDONALD
President and Chief Executive Officer
MANOS PERROS
Chief Executive Officer
MIKE DUDLEYPresident & Chief Executive
Officer
DIAGNOSTICSDiagnostics play a key role in curbing resistance and improving appropriate use of antimicrobials. Hear from diagnostic developers and heads of microbiology on innovative rapid diagnostics and antimicrobial susceptibly tests. Also featured are the presentations from hospitals and pharmacists on the uptake and use of new diagnostics within the hospital setting.
RIBHI SHAWARBranch Chief, Division of Microbiology, CDRH OIVD
CASSANDRA KELLY
Director, Emerging Threats
ERIC WENZLERAssistant Professor,
Department of Pharmacy Practice
KARTIK CHERABUDDI
Director, Antimicrobial Stewardship Program and
Hospital Epidemiologist
MARY MOTYLDirector of Clinical
Microbiology
ROBERT SAMBURSKY
President and Chief Executive Officer
HERMAN GOOSSENS
Project Leader, Value-DX, Director of Research, Laboratory of Medical
Microbiology
EUGEAN JIWANMALLSenior Research Analyst, Technology Evaluation &
Medical Policy
EPHRAIM TSALIK
Professor
NEIL CLANCYAssociate Professor of
Medicine, Infectious Diseases Division, and Director,
Mycology Program
FATIMA BRAKTA
Pharmacy Clinical Manager
ED SEPTIMUSProfessor Internal Medicine
INFECTION CONTROLPreventing infection is one of the most effective and proactive strategies to help curb the spread of resistance. Hear from directors of infection control within hospital and global healthcare leaders on best practices for resistant pathogen protocols, practitioner education and infection prevention strategies.
CHRISTIAN LILLIS
Executive Director
JAY VARMASenior Advisor
ANGELLA BROWNE
Infection Control Officer
CLIFFORD MCDONALDAssociate Director for Science, Division of
Healthcare Quality Promotion, National Center for Emerging
and Zoonotic Infectious Disease
EILI KLEINSenior Fellow
MICHELLE A. BARRON
Medical Director, UCH Infection Prevention and
Control, Professor of Medicine
JEFFREY SILVERS
Medical Director of Pharmacy and Infection Control
KERRY LAPLANTE
President Society of Infectious
Diseases Pharmacists, Professor of Pharmacy,
University of Rhode Island, Adjunct Professor of
Medicine, Brown University
MARISA GLUCOFT
Director, Infection Prevention Control
DANIEL MORGAN
Associate Professor, Epidemiology & Public Health
LINDA LYBERTFounder and Executive
Director
THOMAS HEYMANN
President & Executive Director
MARY MILLARDPatient advocate
STEWARDSHIPAs approaches to antimicrobial stewardship evolve, so do specific stewardship programs, initiatives and practices. Hear from hospitals, industry, insurance companies and stewardship experts on the most innovative approaches to curb resistance and implement appropriate use of antimicrobials.
GIANCARLO FRANCESE
Access Head, Social Impact and Responsibility
DANIEL KNECHT
VP of Health Strategy & Innovation
JILL MASSEYSenior Vice President,
Medical Affairs
ERICA WASHINGTON
Healthcare-associated Infections and Antibiotic
Resistance Program Coordinator
KIM ABBASSClinical Coordinator,
Antimicrobial Stewardship, Eastern Zone
LIZA VAEZICo-Director Antimicrobial
Stewardship Program/ Coordinator Pharmacy and
Therapeutics, Virginia Mason Medical Center, Clinical
Associate Professor
CHARLEY JOHNDirector, US Public Policy
DIRAR ABULLAH
Director of Stewardship
DEBBIE GOFFInfectious Diseases Specialist,
The Ohio State University Wexner Medical Center,
Clinical Associate Professor
JASON POGUEPresident-Elect
ANDREW SHORR
Head of Pulmonary and Critical Care
KALVIN YUMedical Director
BD Digital Health MedMined
REBEKAH MOEHRINGAssociate Professor of
Medicine, Department of Medicine
EDDIE STENEHJEM
Medical Director, Antibiotic Stewardship
MATTHEW GOETZ
Chief, Infectious Diseases
RICK SIBBELFormer Executive Director, US
Food Animal Business Unit
ADAM ZERDADirector, AMR Strategy and
Development
JAYASREE IYERExecutive Director
As funding remains a major hurdle for antibiotic and rapid diagnostics development, hear the perspective of current funding agencies and initiatives such as CARB-X, GARDP, and AMR Centre, as well as successful partnering and capital case studies that contributed to advancing the development of innovative antimicrobials and rapid tests. Over 20+ cutting edge biotechs, academic innovators and diagnostics developers will be presenting new data to prospective funders and partners.
MARK ENGELChief Executive Officer
PRESENTATIONS PITCHES
KAREN GALLANT
Research and Development Chief (Acting), Voting member
of the Joint Oversight Committee
JEAN-PIERRE PACCAUDDirector, Business
Development and Corporate Strategy
PETER JACKSON
Director
WALTER STOCKINGER
Managing Partner
MARY SCHAHEENPresident and Director
CRISTINA MONTEROAssociate Director
RUSTY BROMLEY
Chief Operating Officer
MARC LEMONNIERChief Executive Officer
MARIA NAGYChief Executive Officer
MATTHEW GOMBRICHChief Medical Officer
PIOTR GARSTECKIChief Executive Officer
MONIQUE VAN HOEK
Professor School of Systems Biology
ALEXANDER BELCREDI
Chief Executive Officer
MALCOLM THOMAS
Chief Executive Officer
DAVID LUCIChief Executive Officer
GREG MERRILChief Executive Officer
NEIL CLARKChief Executive Officer
MARC GITZINGER
Chief Executive Officer & Co-Founder
VACCINES & ANTIBIOTIC MANUFACTURING
Vaccines can play key role in combatting the spread of resistance, yet they have been a historically under recognized as a tool for fighting AMR. Hear from biotechs, pharmaceutical companies and funders on both the integration of vaccines into AMR strategies, as well as innovative vaccine development.
Antibiotic manufacturing has several key components impacting the spread of resistance: product quality, waste management and sustainable supply chains. These key elements affect both the efficiency for the manufacturer and also the spread of antimicrobial waste in the environment. Hear from large pharma, generic manufacturers, biotechs, and CMOs/CDMOs on how to improve manufacturing processes to prevent antimicrobial resistance.
VACCINES ANTIBIOTIC MANUFACTURING
GABRIELLE BREUGELMANS
Director of Research
JAIDEEP GOGTAY
Senior Vice President, Global Chief Medical Officer
ALBA TILEYHead of Sustainability
JACQUES DUMAS
Chief Scientific Officer
STEVE BROOKSAdvisor
DALE L. STEMPLE
Head Global EHS - North America and EMEA, Global Environmental, Health and
Safety
MERRIBETH MORIN
Alliance Director
JIM WASSILBusiness Unit Lead, Vaccines,
Patient & Health Impact
ALLISON FLINNAssociate Director, Public Policy and Government
Relations
JAVAD AMANPresident and Chief Scientific
Officer
MARC LIPSITCH
Professor of Epidemiology, Department of Epidemiology, Department of Immunology
and Infectious Diseases, Center for Communicable
Disease Dynamics
JENNY HELLMEN AnalystPublic Health Agency of Sweden
JANE KNISELYProgram Officer, Bacteriology and Mycology BranchNIAID, NIH
BRIAN TSEProject OfficerU.S. Department of Health and Human Services (HHS)
DAVID LUCIChief Executive OfficerAcurx Pharmaceuticals
CHRISTIAN LILLISExecutive DirectorPeggy Lillis Foundation
LINDA LYBERTFounder and Executive DirectorHealthcare Surfaces Institute
MANOS PERROSChief Executive Officer, Entasis Therapeutics
MONIQUE VAN HOEKAssociate ProfessorGeorge Mason University, College of Science
COLM LEONARD Clinical Advisor NICE
KARTIK CHERABUDDIDirector, Antimicrobial Stewardship Program and Hospital EpidemiologistUniversity of Florida
EUGEAN JIWANMALLSenior Research Analyst, Technology Evaluation & Medical PolicyIndependence Blue Cross
CHARLEY JOHNDirector, US Public PolicyWalgreen Co.
RICK SIBBELFormer Executive Director, US Food Animal Business UnitMerck Animal Health
MIKE DUDLEYPresident & Chief Executive OfficerQpex Biopharma
JAIDEEP GOGTAYSenior Vice President, Global Chief Medical OfficerCipla
SARANSH CHAUDHARYChief Executive OfficerVenus Medicine Research Centre
WALTER STOCKINGERManaging PartnerHadean Ventures
JEFFREY SILVERSMedical Director of Quality, Infection Control and PharmacySutter Health
JAY VARMA Senior AdvisorAfrica CDC
KERRY LAPLANTEProfessor of Pharmacy, University of Rhode, Island, Adjunct Professor of Medicine, Brown University
JEREMY KNOXPolicy and Advocacy Lead, Drug-Resistant Infections Program, Wellcome Trust
RICHARD VICKERSSenior Vice President, and Chief ScientificOfficer, Anti-InfectivesSummit Therapeutics
KIM ABBASSClinical Coordinator, Antimicrobial Stewardship, Eastern ZoneNova Scotia Health Authority
GABRIELLE BREUGELMANS Director of ResearchAccess to Medicine Foundation
PETER JACKSONDirectorAMR Centre
NEIL CLANCYAssociate Professor of Medicine, Infectious Diseases Division, and Director, Mycology ProgramUniversity of Pittsburgh
ALEXANDER BELCREDIChief Executive OfficerPhagoMed Biopharma
DANIEL KNECHTVP of Health Strategy & InnovationCVS Health
ALBA TILEYHead of SustainabilityCentrient Pharmaceuticals
MICHELLE BARRONMedical Director, UCH Infection Prevention and ControlUniversity of Colorado Denver
GIANCARLO FRANCESEBoard Member, AMR Industry Alliance, Access Head, Social Impact and ResponsibilityTeva
STEVE BROOKSAdvisorAMR Industry Alliance
NICK VAN HISEInfectious Disease Clinical Pharmacy Specialist, Research CoordinatorMetro Infectious Disease Consultants
GREG MERRILChief Executive OfficerAdaptive Phage Therapeutics
CHRISTINE ARDALSenior Advisor, EU-JAMRAINorwegian Institute of Public Health
KEVIN OUTTERSONProfessor, Boston University, Executive DirectorCARB-X
ABIGAIL COLSONLecturer, Department of Management ScienceUniversity of Strathclyde Glasgow
GUY MACDONALDPresident and Chief Executive OfficerTetraphase Pharmaceuticals
JEANETTE MUCHACEO, Chief Science Officer and Co-FounderScibac
ANGELLA BROWNEInfection Control OfficerHoward University Hospital
MALCOLM THOMASChief Executive OfficerAgile Sciences
PETER BEYERSenior Advisor, World Health Organization
MARY MILLARDPatient AdvocateSepsis Survivor
FATIMA BRAKTAPharmacy Clinical ManagerUniversity Medical Center of New Orleans
EILI KLEINSenior FellowCenter for Disease Dynamics, Economics & Policy
JIM WASSILBusiness Unit Lead, VaccinesPatient & Health Impact, Pfizer
DEBRA GOFFInfectious Diseases Specialist, The Ohio State University Wexner Medical Center, Clinical Associate Professor, Ohio State University Medical Center
JAVAD AMANPresident and Chief Scientific OfficerIntegrated Biotherapeutics
JUSTINE ABELLA ROSSInfectious Diseases Pharmacist, Chair Antimicrobial Stewardship Program, Department of Pharmacy ServicesCity of Hope National Medical Center
MARK ENGELChief Executive OfficerPhagelux
THIERRY BERNARDIChief Executive OfficerBiofilm Pharma
ROBERT SAMBURSKYPresident and Chief Executive OfficerRPS Diagnostics
NEIL CLARKChief Executive OfficerDestiny Pharma
MONIKA SCHNEIDERResearch AssociateDuke-Margolis Center for Health Policy
MARIA NAGYChief Executive OfficerQuorum X Diagnostics
JASON POGUEPresident-ElectSociety of Infectious Disease Pharmacists (SIDP)
KAREN GALLANTResearch and Development Chief (Acting) and voting member of the Joint Oversight CommitteeCARB-X
200+ SPEAKERS INCLUDING
RUSTY BROMLEYChief Operating OfficerAyuVis Research
RYAN DAVIESChief Executive OfficerCurza
MARCO TAGLIETTIPresident, Chief Executive OfficerSCYNEXIS
GARETH MORGANGlobal Portfolio ManagementShionogi
LIZA VAEZICo-Director Antimicrobial Stewardship Program/ Coordinator Pharmacy and Therapeutics, Virginia Mason Medical Center, Clinical Associate ProfessorUniversity of Washington
GUL MADISONHead of Infectious DiseaseMercy Philadelphia Hospital
REBEKAH MOEHRINGInfectious Diseases Physician, Duke Center for Antimicrobial StewardshipDuke University
DAVE POWELLSVP, ResearchSummit Therapeutics
THOMAS HEYMANNPresident & Executive DirectorSepsis Alliance
MERRIBETH MORINAlliance DirectorCARB-X
JAYASREE IYERExecutive DirectorAccess to Medicine Foundation
PAUL PLUMMERExecutive DirectorNational Institute of Antimicrobial Resistance Research and Education (NIAMRRE)
EPHRAIM TSALIKProfessorDuke University School of Medicine
JACQUES DUMASChief Scientific OfficerTetraphase Pharmaceuticals
MARC GITZINGERCEO and Co-FounderBioVersys AG
PAMELA TENAERTSExecutive DirectorClinical Trials Transformation Initiative (CTTI)
ALEKS ENGELDirector, REPAIR Impact FundNovo Holdings
JONATHAN VAN-TAMDeputy Chief Medical Officer, UK Department of Health
HERMAN GOOSSENSProject Leader, VALUE-Dx, Director of Research, Laboratory of Medical MicrobiologyUniversity of Antwerp
ALLISON FLINNLead, North America Public PolicyMerck Animal Health
CRISTINA MONTEROAssociate DirectorTechAtlas, RA Capital Management
MELISSA STUNDICKExecutive Director of Strategic AlliancesSpero Therapeutics
MARK ALBRECHTChief (acting) Antibacterials BranchBARDA
RIBHI SHAWARBranch Chief, Division of Microbiology, CDRH, OIVDFood and Drug Administration
EDDIE STENEHJEMMedical Director, Antibiotic StewardshipIntermountain Healthcare
ADAM ZERDADirector, AMR Strategy and DevelopmentBD
CLIFF MCDONALDAssociate Director for Science, Division of Healthcare Quality PromotionNational Center for Emerging and Zoonotic Infectious Disease, Centers for Disease Control
KALVIN YUMedical DirectorBD Digital Health MedMined
LEE JONESPresident and Chief Executive OfficerRebiotix Inc
CARA CASSINOEVP Research and Development and Chief Medical OfficerContrafect
RITA OLANSAssistant Professor, School of NursingMGH Institute of Health Professions
MARC LEMONNIERChief Executive OfficerAntabio
ED SEPTIMUSSenior Lecturer, Department of Population MedicineTexas A&M Health Science Center
JILL MASSEYSenior Vice President, Medical AffairsMelinta Therapeutics
ANDREW SHORRDirector of Pulmonary and Critical CareWashington Health Center
PIOTR GARSTECKIChief Executive OfficerBacteromic
MARY SCHAHEENPresident and DirectorPrevail Partners
TERRY ROEMERPresident and Chief Scientific OfficerProkaryotics Inc.
MICHAEL BEVILACQUAChief Executive OfficerAmicrobe
EVAN LOHChairman, Antimicrobials Working Group, President, Chief Operating Officer, Chief Medical OfficerParatek Pharmaceuticals, Inc.
BRIAN LUBBERSDirector of the Clinical MicrobiologyKansas State Veterinary Diagnostic Laboratory
ERICA WASHINGTONHealthcare-associated Infections and Antibiotic Resistance Program CoordinatorLouisiana Department of Health
DANIEL MORGANAssociate Professor of Epidemiology and MedicineUniversity of Maryland School of Medicine
MATTHEW GOMBRICHChief Medical OfficerAperture Bio
ANTHONY LAKAVAGESenior Vice-President, Global External AffairsUS Pharmacopia
BRUCE ALTEVOGTVice President and Head External Medical Engagement, Hospital Business UnitPfizer
ERIC WENZLERAssistant Professor, Department of Pharmacy PracticeUniversity of Illinois at Chicago College of Pharmacy
ZAK ZIMMERMANCEO & CofounderForge Therapeutics
SHEILA CONNELLYVice President, ResearchSynthetic Biologics
200+ SPEAKERS INCLUDING
AMANDA JEZEKSenior Vice President, Public Policy and Government RelationsInfectious Diseases Society of America
JEAN-PIERRE PACCARDDirector of Business Development and Corporate StrategyGlobal Antibiotic R&D Partnership (GARDP)
DENNIS MICHAEL DIXONChief Bacteriology and Mycology BranchNIAID-NIH
CASSANDRA KELLYDirector, Emerging ThreatsFIND
MARISA GLUCOFTDirector, Infection Prevention ControlChildren’s Hospital Los Angeles
THOMAS FILEAntimicrobial Stewardship Program at Summa Health, Akron, President-ElectInfectious Disease Society of America (IDSA)
JOHN JOHNSONChief Executive Officer and Director Melinta Therapeutics
DALE STEMPLEVice-President Global EHSMylan
MARC LIPSITCHProfessor of Epidemiology, Department of Epidemiology, Department of Immunology and Infectious Diseases, Center for Communicable Disease DynamicsHarvard T.H. Chan School of Public Health
SUSAN DAVISClinical Professor, Pharmacy Practice, Wayne State University, Infectious Diseases PharmacistHenry Ford Health System
PAUL GAROFOLOChief Executive Officer, Chairman of the Board, & Co-FounderLocus Biosciences
TOM TURCOClinical PharmacistMercy Philadelphia Hospital
DAVE OUSTEROUTChief Scientific Officer & Co-FounderBioVersys AG
CO
NFE
RENCE
DAY ONE
THURSDAY, NOVEMBER 7TH, 2019
PLENARY KEYNOTES
CONCRETE COMMERCIAL INITIATIVES
Open panel & audience Q&A: Analyzing the potential impact of current commercial and “pull” initiativesModerator: Kevin Outterson, Professor, Boston University, Executive Director, CARB-XAleks Engel, Director, REPAIR Impact Fund, Novo Holdings Melissa Stundick, Executive Director, Strategic Alliances, Spero TherapeuticsJeremy Knox, Director of Policy, Drug Resistant Infections, Wellcome TrustEvan Loh, Chairman, Antimicrobials Working Group, President, Chief Operating Officer, Chief Medical Officer, Paratek PharmaceuticalsAmanda Jezek, Senior Vice President, Public Policy and Government Relations, Infectious Diseases Society of America
9:40
Keynote address: A vision for a healthy antibiotic R&D ecosystemKevin Outterson, Professor, Boston University, Executive Director, CARB-X
8:40
11:15
Keynote address: UK’s efforts to combat resistance and create a sustainable commercial environment for existing and future antibioticsJonathan Van-Tam, Deputy Chief Medical Officer, UK Department of Health
9:00
ANTIBIOTIC R&D
How BARDA incentivizes antibacterial development from early development through marketing approvalMark Albrecht, Chief (acting) Antibacterials Branch, BARDA
9:40
8:40
9:00
ANTIMICROBIAL STEWARDSHIP
Stewardship efforts among generic antibiotic manufacturers - Uniting generics through AMR Industry Alliance to increase global stewardship Giancarlo Francese, Access Head, Social Impact and Responsibility, TEVA
DIAGNOSTICS
Diagnostic devices for antimicrobial susceptibility and resistance - FDA update on recent initiatives and advancementsRibhi Shawar, Branch Chief, Division of Microbiology, CDRH, OIVD, FDA
SPEED NETWORKING FOLLOWED BY NETWORKING COFFEE BREAK10:20
Early Development Development Stewardship Partnerships
11:35 Oral Ceftriaxone - a proof-of-concept for a novel drug delivery platform Saransh Chaudhary, Chief Executive Officer, Venus Medicine Research Centre
Big data to improve antibiotic prescribing: CVS Health-Aetna’s multi-stakeholder approach Daniel Knecht, VP of Health Strategy & Innovation, CVS Health
Thinking creatively about diagnostic development – breaking from constraints of conventional development and delivery modelsCassandra Kelly, Director, Emerging Threats, FIND
How degrading residual antibiotics in the GI tract may prevent the emergence of anti-microbial resistance in the gut microbiomeSheila Connelly, Vice President of Research, Synthetic Biologics
Real world registry evidence in support of antimicrobial stewardshipJill Massey, Senior Vice President, Medical Affairs, Melinta Therapeutics
INFECTION CONTROL
Preventing infections in African health facilities through laws and standardsJay Varma, Senior Advisor, Africa Centres for Disease Control and Prevention
Guidelines and Regulation
Determining your Hospital’s Infection Control protocols and ensuring facility-wide compliance - Balancing hospital resources, expertise and with regulatory standards
Current state by state regulations for hospital infection reporting, safety and infection control standards, and reality of nation-wide regulation for hospital infection reporting?
MANUFACTURING
Ensuring a sustained availability of high-quality antibiotics - considerations for manufacturing, quality testing, transport, poor quality drugs, and the role of customersJaideep Gogtay, Senior Vice President, Global Chief Medical Officer, Cipla
Supply Chain
Collaborating along the value chain for sustainably made antibiotics: roles of manufacturers and buyersAlba Tiley, Head of Sustainability, Centrient Pharmaceuticals
Synthesizing complex molecules for antibacterial products – manufacturing challenges and opportunitiesJacques Dumas, Chief Scientific Officer, Tetraphase Pharmaceuticals
Host-based diagnostics fordiscriminating bacterial and viralinfection – diagnostic performance inpatients in international and resourcelimited environmentsEphraim Tsalik, Professor, Duke University School of Medicine
CARB-X – accelerating innovation to fight drug-resistant bacteria Karen Gallant, Research and Development Chief (Acting), Voting member of the Joint Oversight Committee, CARB-X
Funding & Innovation
Utilizing bacteriophages to prevent infections: an updateMark Engel, Chief Executive Officer, Phagelux
Biotech Pitches
Developing phage drugs as first-line therapiesAlexander Belcredi, Chief Executive Officer, PhagoMed Biopharma
Overcoming bacterial resistance through a new and unique mode of actionMalcolm Thomas, Chief Executive Officer, Agile Sciences
11:15
10:20
11:35
11:55
12:05
Sponsored keynote addressTITLE SPONSOR SLOT If you are interested in sponsoring this session in the Antibiotic R&D Track, contact André Singer now at +1 646 619 1797 or [email protected]
9:20 9:00
11:55
CO
NFE
RENCE
DAY ONE
THURSDAY, NOVEMBER 7TH, 2019
12:15 GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Antibiotic R&D Track, contact André Singer now at +1 646 619 1797 or [email protected]
GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Antimicrobial Stewardship Track, contact André Singer now at +1 646 619 1797 or [email protected]
GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Diagnostics Track, contact André Singer now at +1 646 619 1797 or [email protected]
NETWORKING LUNCH BREAK12:35
Early Development Development Stewardship Partnerships
ANTIBIOTIC R&DANTIMICROBIAL STEWARDSHIP
GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Infection Control Track, contact André Singer now at +1 646 619 1797 or [email protected]
Guidelines and Regulation
INFECTION CONTROL
GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Manufacturing Track, contact André Singer now at +1 646 619 1797 or [email protected]
Supply Chain
MANUFACTURINGDIAGNOSTICS
12:25
ACX-362E and ACX-375C to treat serious and life- threatening bacterial infectionsDavid Luci, Chief Executive Officer, Acurx Pharmaceuticals
Biotech Pitches
PhageBank - Advancing personalized phage therapy from niche to broad market scaleGreg Merril, Chief Executive Officer, Adaptive Phage Therapeutics
1:05 Keynote Address: What companies are doing to combat AMR and support appropriate use of anti-infective medicinesModerator: available for sponsorshipBruce Altevogt, Vice President and Head External Medical Engagement, Hospital Business Unit, Pfizer Inc.Jayasree K. Iyer, Executive Director, Access to Medicine Foundation
NETWORKING LUNCH RESUMES 1:35
Roundtable 1: Animal Health – examining stewardship progress in managing antibiotic use and potential AMR in Animal HealthModerator: Rick Sibbel, Former Executive Director, US Food Animal Business Unit, Merck Animal Health
Brian Lubbers, Associate Professor, Kansas State University
Paul Plummer, Executive Director, National Institute of Antimicrobial Resistance Research and Education (NIAMRRE)
ROUNDTABLES2:10
Roundtable 2: Controlling c.diff – determining who to test how to prevent additional outbreaks in the hospitalKartik Cherabuddi, Director, Antimicrobial Stewardship Program and Hospital Epidemiologist, University of Florida
Roundtable 3: Innovation & stewardship – Advancing narrow spectrum, new mechanism antibiotics as precision agents to by-pass resistance and to support antibiotic stewardship. Developing the right antibiotic to treat the right patient and improve clinical outcomes.Dave Powell, Head of Research and SVP, Summit Therapeutics Richard Vickers, Chief Scientific Officer and SVP, Antimicrobials, Summit Therapeutics
Roundtable 4: Customizing Epic – use of Epic Stewardship Navigator to aid antimicrobial stewardship, pharmacist workflow, and prescribing habits in a tertiary cancer center Justine Ross, Infectious Diseases Pharmacist, Chair Antimicrobial Stewardship Program, Department of Pharmacy Services, City of Hope National Medical Center
Roundtable 5: Antimicrobial value assessment – a look into the role of HTA in the UK’s testing of novel assessment and delinked payment programColm Leonard, Clinical Advisor, The National Institute for Health and Care Excellence (NICE)
Roundtable 6: Policy in Africa – advancing advocacy, political commitment, resistance data collection and Africa-wide stewardship guidelines for antimicrobial use in humans Jay Varma, Senior Advisor, Africa Centres for Disease Control and Prevention
Roundtable 7: Non-traditional antibacterials – advancing non-traditional product types from discovery phase to clinical developmentBrian Tse, Health Scientist, BARDA
Roundtable 8: Advancing preclinical – working with regulators through pre-clinical to advance distinct classes of small molecule drugsRyan Devies, Chief Executive Officer, Curza
Roundtable 9: Supporting development – NIH programs filling the gaps in traditional and non-traditional therapeutic discovery & development with grants, contracts, in-vitro and in vivo screening and manufacturing capabilities and moreJane Knisely, Program Officer, NIH-NIAID
Roundtable 10: Market access – overcoming access barriers for smaller markets and considerations for countries and developersChristine Årdal, Senior Advisor, EU-JAMRAI, Norwegian Institute of Public Health
Roundtable 11: Patient advocacy – what can the growing antibiotic patient advocacy community do to generate public awareness and support for AMR initiatives Christian Lillis, Executive Director, Peggy Lillis Foundation
Roundtable 12: Stewardship Training – educating nurses on stewardship best practicesRita Olans, Assistant Professor, School of Nursing, MGH Institute of Health Professions
12:15
12:35
12:25
1:05
1:35
2:10
CO
NFE
RENCE
DAY ONE
THURSDAY, NOVEMBER 7TH, 2019
3:15 Novel trial designs for non-traditional anti-infectives – lessons learned from the Exebacase superiority design trialCara Cassino, Chief Medical Officer and Executive Vice President of Research and Development, ContraFect
A coordinated approach to state-wide stewardship goalsErica Washington, Healthcare-associated Infections and Antibiotic Resistance Program Coordinator, Louisiana Department of Health
A-Z of hospital and pharmacy use of new and existing rapid diagnostics –diagnosing multi drug resistant organisms Eric Wenzler, Assistant Professor, Department of Pharmacy Practice, University of Illinois at Chicago College of Pharmacy
Trial Design Diagnostics in the Hospital In-patient
ANTIBIOTIC R&DANTIMICROBIAL STEWARDSHIP
DIAGNOSTICS
3:35 Working with regulators to advance non-traditional therapies to prevent and treat life-threatening infections in surgery and traumaMichael P. Bevilacqua, Chief Executive Officer, Amicrobe
Implementation of an antimicrobial stewardship program across a multi-site health system - A Canadian Perspective Kim Abbass, Antimicrobial Stewardship, Eastern Zone, Nova Scotia Health Authority
Early detection of Pseudomonas aeruginosa biofilms in non-cystic fibrosis bronchiectasis, are we there yet?Laia Fernandez, BioFilm Pharma
3:55 Panel: efforts to tackle the toughest clinical trials for antibiotic development - HABP/VABP & blood stream infections and moreModerator: Marina Kozak, Biologist, Division of CBRN Countermeasures, HHS/BARDA
Pamela Tenaerts, Executive Director, Clinical Trials
Dennis Michael Dixon, Chief Bacteriology and Mycology Branch, NIAID-NIH
When and how to prescribe new agents - best practices for understanding resistance and effectiveness of new antibiotics Liza Vaezi, Co-Director Antimicrobial Stewardship Program/ Coordinator Pharmacy and Therapeutics, Virginia Mason Medical Center, Clinical Associate Professor, University of Washington
Panel: Evaluating novel diagnostics for hospital use and uptake in the clinic– considerations for cost, personnel training, and microbiologist collaboration Moderator: available for sponsorship
Neil Clancy, Associate Professor of Medicine, Infectious Diseases Division, and Director, Mycology Program, University of Pittsburgh
Fatima Brakta Pharmacy Clinical Manager, University Medical Center of New Orleans
Ed Septimus, Professor Internal Medicine, Texas A&M Health Science Center
4:15 AntiMicrobials 2.0 - new anti-infective arsenal that targets the chronic infectionsThierry Bernardi, Chief Executive Officer, BioFilm Pharma
Screening for gram negative bacteria – when to screen, who to screen, how to screen?Michelle A. Barron, Medical Director, UCH Infection Prevention and Control, Professor of Medicine, University of Colorado Denver
AMR manufacturing environmental updateSteve Brooks, Advisor, AMR Industry Alliance
Resistant Pathogen Protocol & Practices
Waste Management
INFECTION CONTROL MANUFACTURING
C. diff and C-suite headaches-reimbursement, outbreaks, and recurrenceKerry LaPlante, President, Society
of Infectious Diseases Pharmacists (SIDP),
Professor of Pharmacy, University of Rhode Island, Adjunct Professor of Medicine, Brown University
Future outlook & best practices for manufacturing to reduce AMR: sustainable frameworks and emerging technologies Dale L. Stemple, Head Global EHS - North America and EMEA, Global Environmental, Health and Safety Mylan
Isolation - when to isolate, who to isolate - Is healthcare moving away from isolation?Daniel Morgan, Associate Professor, Epidemiology & Public Health, University of Maryland School of Medicine
Environmental exposure, risk assessment and dissemination of AMR - comparing global regions and current waste management practices
GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Infection Control Track, contact André Singer now at +1 646 619 1797 or [email protected]
GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Manufacturing Track, contact André Singer now at +1 646 619 1797 or [email protected]
Leveraging sources of public funding to meet gaps in S&M antibiotic financing - how can we avoid the catastrophic disappearance of S&M companies and their unique competencies in antibiotic discovery and developmentJean-Pierre Paccaud, Director, Business Development and Corporate Strategy, Global Antibiotic R&D Partnership (GARDP)
Funding & Partnerships
UK Centre of Excellence - a global resource for pre-clinical and clinical development, and mobilizing public, private and philanthropic investmentPeter Jackson, Director, AMR Centre
Biotech Pitches
XF-73 for the prevention of post-surgical staphylococcal infectionsNeil Clark, Chief Executive Officer, Destiny Pharma
A novel immunotherapy to fight infection and inflammationRusty Bromley, Chief Operating Officer, AyuVis Research
Antabio SAS: novel antibacterials targeting critical priority MDR gram-negative pathogensMarc Lemonnier, Chief Executive Officer, Antabio
BV100 to treat serious bacterial infections by A.baumanniiMarc Gitzinger, Chief Executive Officer & Co-Founder, BioVersys AG
NETWORKING COFFEE BREAK 4:35
3:15
3:35
3:55
4:05
4:15
4:25
4:35
ROUNDTABLES2:10
Roundtable 13: Phage development – Opportunities in development of noval phage therapiesDave Ousterout, Chief Scientific Officer & Co-Founder, Locus Biosciences
2:10
CO
NFE
RENCE
DAY ONE
THURSDAY, NOVEMBER 7TH, 2019
PLENARY KEYNOTES
SUPPORTED BY BD
Keynote Panel: benchmarking and risk-adjusting antimicrobial use: success, barriers, and future
Moderator: Kalvin Yu, Medical Director, BD Digital Health MedMined
Adam Zerda, Director, AMR Strategy and Development, BD
Rebekah Moehring, Associate Professor of Medicine, Department of Medicine, Duke University School of Medicine
Cliff MacDonald, Associate Director for Science, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Disease, Centers for Disease Control
Eddie Stenehjem, Medical Director, Antibiotic Stewardship, Intermountain Healthcare
Matthew Goetz, Chief, Infectious Diseases, VA Greater Los Angeles Healthcare System
5:15
DRINKS RECEPTION 6:05
5:15
6:05
Register now at www.terrapinn.com/antimicrobial
CO
NFE
RENCE
DAY TWO
FRIDAY, NOVEMBER 8TH, 2019
PLENARY KEYNOTES
SHIFTING PARADIGMS
Keynote address: 360 of hospital purchasing and antibiotic use – understanding price-based vs stewardship-based purchasing decisions for new antibiotics & diagnostics
Moderator: Debbie Goff, Infectious Diseases Specialist, The Ohio State University Wexner Medical Center, Clinical Associate Professor, The Ohio State University College of PharmacyJason Pogue, President-Elect, Society of Infectious Disease Pharmacists (SIDP)Andrew Shorr, Head of Pulmonary and Critical Care, Medicine Washington Health Center Thomas File, Antimicrobial Stewardship Program at Summa Health, Akron, President-Elect, Infectious Disease Society of America (IDSA)
9:50
Keynote address: Patient and public outcry – examining the human impact of AMR and how we can make it a mainstream issue Mary Millard, Patient Advocate, Sepsis SurvivorChristian Lillis, Executive Director, Peggy Lillis Foundation
9:00
11:15
Sponsored keynote addressPLATINUM SPONSOR SLOT - If you are interested in sponsoring this plenary session, contact André Singer now at +1 646 619 1797 or [email protected]
9:25
ANTIBIOTIC R&D
Pilot reimbursement models to ensure access of new antibiotics in Sweden - Collaboration between industry and government agencies to ensure a model that works for all stakeholdersJenny Hellman, Analyst, Public Health Agency of Sweden
ANTIMICROBIAL STEWARDSHIP
Pharmacists on the front lines of outpatient care- Examining the critical role pharmacists & point of care diagnostics play in appropriate outpatient antibiotic useCharley John, Director, US Public Policy, Walgreen Co.
DIAGNOSTICS
Reversing the “pitch” between diagnostics providers and industry - benefits and feasibility of pharma communicating their needs diagnostic developers first to accelerate development of badly needed tests Mary Motyl, Director of Clinical Microbiology, Merck and Co
NETWORKING COFFEE BREAK10:30
Commercial & Partnerships Industry Collaboration Out-patient
11:15
11:35 Short and long-term payment strategies for a sustainable market – impact of NTAP modifications, DRG carve-out, and potential subscription modelsMonika Schneider, Research Associate, Duke Margolis Center for Health Policy
Urgent care – antibiotic stewardship’s new frontier? Eddie Stenehjem, Medical Director, Antibiotic Stewardship, Intermountain Healthcare
Diagnostic engagement through antibiotic clinical development & commercialization – can further collaboration be attached to collectively tackle AMR?
Panel: How to foster private investment in antibiotic development? Exploring an impact investment fund Peter Beyer, Senior Advisor, World Health Organization
Marc Gitzinger, Chief Executive Officer and Co-Founder, BioVersys AG
Transition of care in antimicrobial stewardship from in-patient to out-patient- exploring barriers and solutions to optimize antibiotic useSusan Davis, Clinical Professor, Pharmacy Practice, Wayne State University, Infectious Diseases Pharmacist, Henry Ford Health System
INFECTION CONTROL
Making sense of all the infection control guidelines for surfaces and environments in hospitals Linda Lybert, Founder and Executive Director, Healthcare Surfaces Institute
MANUFACTURING
Linking vaccine use to AMR reduction – Do we have enough evidence to convince policy makers to incorporate vaccines into broader AMR strategiesJim Wassil, Business Unit Lead, Vaccines, Patient & Health Impact, Pfizer
Environment & Cleaning Uptake and prevention
GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Infection Control Track, contact André Singer now at +1 646 619 1797 or [email protected]
The role of vaccination in Antimicrobial Stewardship (AMS) and Merck’s One Health approach to tackling the challenge of AMRAllison Flinn, Associate Director, Public Policy and Government Relations, Merck Animal Health
Panel: Getting C-suite buy-in for new hospital infection control products and technologies - weighing risks and liabilities of taking on new infection control technologies Moderator: available for sponsorshipJeffrey Silvers, Medical Director of Pharmacy and Infection Control Sutter HealthMarisa Glucoft, Director, Infection Prevention Control, Children’s Hospital Los Angeles
A novel toxoid vaccine targeting Staphylococcus aureus virulenceJavad Aman, President and Chief Scientific Officer, Integrate BioTherapeutics
GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Diagnostics Track, contact André Singer now at +1 646 619 1797 or [email protected]
11:55
Investors Panel: Promising science in the field of antibiotic diagnostics and how developers can best approach investors Moderator: available for sponsorship
Walter Stockinger, Managing Partner, Hadean Ventures
Mary Schaheen, President and Director, Prevail Partners
Cristina Montero, Associate Director, TechAtlas RA Capital Management
Investment
Quorum X Diagnostics: A new way of identifying bacteria, without the need for culture or DNA amplificationMaria Nagy, Chief Executive Officer, Quorum X Diagnostics
Aperture Bio empiriSTAT UTI: A rapid, direct-out-of-urine method for addressing the rise in antibiotic resistance in urinary tract infectionsMatthew Gombrich, Chief Medical Officer, Aperture Bio
Diagnostics Pitches
9:50
9:00
11:15
9:25
10:30
11:15
11:35
11:55
12:05
CO
NFE
RENCE
DAY TWO
FRIDAY, NOVEMBER 8TH, 2019
ANTIBIOTIC R&DANTIMICROBIAL STEWARDSHIPDIAGNOSTICS
Commercial & Partnerships Industry Collaboration Out-patient
Panel discussion continued
INFECTION CONTROL MANUFACTURING
Environment & Cleaning Uptake and prevention
Panel discussion continued GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Manufacturing Track, contact André Singer now at +1 646 619 1797 or [email protected]
Session continued GOLD SPONSOR SESSION If you are interested in sponsoring this session in the Antimicrobial Stewardship Track, contact André Singer now at +1 646 619 1797 or [email protected]
12:15
12:25
12:15
Diagnostics Pitches
Bacteromic: Intelligence for precision therapies against antimicrobial resistancePiotr Garstecki, Chief Executive Officer, Bacteromic
Academia Pitches
Discovery of antimicrobial peptides from alligator and komodo dragons against multi-drug resistant bacteriaMonique van Hoek, Professor School of Systems Biology, George Mason University
NETWORKING LUNCH BREAK 12:35
C-Suite Keynote Panel: Balancing continued innovation in R&D while navigating funding, stewardship and the overall commercial landscape
Moderator: available for sponsorship Manos Perros, Chief Executive Officer, Entasis TherapeuticsMike Dudley, President & Chief Executive Officer, Qpex BiopharmaDavid Roblin, Chief Operating Officer, Chief Medical Officer, President of R&D, Summit TherapeuticsGuy Macdonald, President and Chief Executive Officer, Tetraphase
1:00
NETWORKING LUNCH BREAK RESUMES 1:40
Roundtable 1: Moving policy forward – payment reform, public perception and continued efforts in 2020 Moderator: Jeremy Knox, Senior Investment Director, Wellcome Trust
Monika Schneider, Research Associate, Duke Margolis Center for Health Policy
ROUNDTABLES2:10
Roundtable 2: The fecal microbiome – new approaches to the treatment of C. difficile infectionNick VanHise, Infectious Disease Clinical Pharmacy Specialist, Research Coordinator, Metro Infectious Disease Consultants & Cdiff Foundation
Roundtable 3: Evaluating Diagnostics – Criteria for potential coverage and related decisions - paths for generating, formalizing, & analysing evidence to build & reach consensusEugean Jiwanmall, Senior Research Analyst, Technology Evaluation & Medical Policy, Independence Blue Cross
Roundtable 4: AMR and Sepsis – we are all in this togetherThomas Heymann, President & Executive Director, Sepsis Alliance
Roundtable 5: Surveillance – examining novel metrics for measurement, societal and socioeconomic factors effecting resistance, and how resistance surveillance tools can help educate policymakers on AMR Eili Klein, Fellow, Center for Disease Dynamics, Economics & Policy
Roundtable 6: Stewardship best practices – highlights of specific hospital protocols and team collaborationsGul Madison, Head of Infectious Disease, Mercy Philadelphia Hospital Tom Turco, Clinical Pharmacist, Mercy Philadelphia Hospital
Roundtable 7: Infection prevention – next wave of infection prevention of multidrug resistant infections through screening, protocol and moreAngella Browne, Infection Control Officer, Howard University Hospital
Roundtable 8: CARB-X accelerator – company perspective on CARB-X Accelerator - What worked and what can be improved? Jeanette Mucha, CEO, Chief Science Officer and Co-Founder, Scibac
Roundtable 9: Health Technology Assessment – when it comes to AMR, will HTA be part of the solution or part of the problem? Abigail Colson, Lecturer, Department of Management Science, University of Strathclyde Glasgow
Roundtable 10: Microbiome & CDC – Discussing a vision for precision public health and novel approaches to infection prevention through the microbiomeClifford McDonald, Associate Director for Science, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Disease, Centers for Disease Control
12:35
1:00
1:40
2:10
CO
NFE
RENCE
DAY TWO
FRIDAY, NOVEMBER 8TH, 2019
ROUNDTABLES2:10
Roundtable 11: The role of vaccines in controlling AMRMarc Lipsitch, Professor of Epidemiology, Department of Epidemiology, Department of Immunology and Infectious Diseases, Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health
Roundtable 12: Infection intervention – using the microbiome to make antibiotics effective againLee Jones, President and Chief Executive Officer, Rebiotix
Roundtable 13: Patient practitioner education – how hospitals can and should educate patients on infection risks and easy to implement prevention practices Mary Millard, Patient advocate, Sepsis Survivor
3:15 Innovative business partnerships to build a portfolio of novel antibioticsZak Zimmerman, Chief Executive Officer, Forge Therapeutics
FebriDx: A POC test that simultaneously detects MxA and CRP during presumed acute respiratory infection to improve clinical workflow, reduce unnecessary antibiotics, and save costsRobert Sambursky, President and Chief Executive Officer, RPS Diagnostics
Early Development Development
ANTIBIOTIC R&D DIAGNOSTICS
3:35 Rationale for in-licensing early stage antibacterial assetsTerry Roemer, President and Chief Scientific Officer, Prokaryotics
VALUE-DX: generating evidence on the medical, economic, and public health value of diagnostics in tackling AMRHerman Goossens, Project Leader, Value-DX, Director of Research, Laboratory of Medical Microbiology, University of Antwerp
END OF CONFERENCE3:55
2:10
3:15
3:35
3:55
Register now at www.terrapinn.com/antimicrobial
Roundtable 14: Candida auris – a ticking time bomb: responding to an urgent global public health threatMarco Taglietti, President, Chief Executive Officer, SCYNEXIS
ROUNDTABLES1. Animal Health – examining progress in made within curbing AMR and antibiotic use within animal healthModerator: Rick Sibbel, Former Executive Director, US Food Animal Business Unit, Merck Animal Health
Brian Lubbers, Associate Professor, Kansas State University
Paul Plummer, Executive Director, National Institute of Antimicrobial Resistance Research and Education (NIAMRRE)
2. Controlling c.diff – determining who to test how to prevent additional outbreaks in the hospitalKartik Cherabuddi, Director, Antimicrobial Stewardship Program and Hospital Epidemiologist, University of Florida
3. Innovation & stewardship Dave Powell, Head of Research and SVP, Summit Therapeutics
Richard Vickers, Chief Scientific Officer and SVP, Antimicrobials, Summit Therapeutics
4. Customizing Epic – use of Epic Stewardship Navigator to aid antimicrobial stewardship, pharmacist workflow, and prescribing habits in a tertiary cancer center Justine Ross, Infectious Diseases Pharmacist, Chair Antimicrobial Stewardship Program, Department of Pharmacy Services, City of Hope National Medical Center
5. Antimicrobial value assessment – a look into the role of HTA in the UK’s testing of novel assessment and delinked payment programColm Leonard, Clinical Advisor, The National Institute for Health and Care Excellence (NICE)
6. Policy in Africa – advancing advocacy, political commitment, resistance data collection and Africa-wide stewardship guidelines for antimicrobial use in humans Jay Varma, Senior Advisor, Africa Centres for Disease Control and Prevention
7. Non-traditional antibacterials – advancing non-traditional product types from discovery phase to clinical developmentBrian Tse, Health Scientist, BARDA
8. Advancing preclinical – working with regulators through pre-clinical to advance distinct classes of small molecule drugsRyan Devies, Chief Executive Officer, Curza
9. Supporting development – NIH programs filling the gaps in traditional and non-traditional therapeutic discovery & development with grants, contracts, in-vitro and in vivo screening and manufacturing capabilities and moreJane Knisely, Program Officer, NIH-NIAID
10. Moving policy forward – payment reform, public perception and continued efforts in 2020 Moderator: Jeremy Knox, Senior Investment Director, Wellcome Trust
Monika Schneider, Research Associate, Duke Margolis Center for Health Policy
11. The fecal microbiome – new approaches to the treatment of C. difficile infectionNick VanHise, Infectious Disease Clinical Pharmacy Specialist, Research Coordinator, Metro Infectious Disease Consultants & Cdiff Foundation
12. Infection prevention – next wave of infection prevention of multidrug resistant infections through screening, protocol and moreAngella Browne, Infection Control Officer, Howard University Hospital
16. Microbiome & CDC – Discussing a vision for precision public health and novel approaches to infection prevention through the microbiomeClifford McDonald, Associate Director for Science, Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Disease, Centers for Disease Control
17. Infection intervention – using the microbiome to make antibiotics effective againLee Jones, President and Chief Executive Officer, Rebiotix
18. Patient practitioner education – how hospitals can and should educate patients on infection risks and easy to implement prevention practices Mary Millard, Patient advocate, Sepsis Survivor
14. Stewardship Training – educating nurses on stewardship best practices Rita Olans, Assistant Professor, School of Nursing, MGH Institute of Health Professions
15. Health Technology Assessment – when it comes to AMR, will HTA be part of the solution or part of the problem? Abigail Colson, Lecturer, Department of Management Science, University of Strathclyde Glasgow
13. CARB-X accelerator – company perspective on CARB-X Accelerator - What worked and what can be improved? Jeanette Mucha, CEO, Chief Science Officer and Co-Founder, Scibac
Good opportunities for pipeline information, networking, and potentially presenting your own companies’ data
Clinical Solutions Executive, Cepheid
Attendance by key global players … Absolutely a case of “Be there or be square!”
Executive Vice President, Recce Pharmaceuticals
Quite interactive, very good opportunity to learn about future trends
Head of Marketing & Scientific Affairs, Curetis GmbH
Great opportunity to network, and hear the perspectives of CEOs, FDA and other key health leaders on issues related to antimicrobial resistance
Infectious Diseases Specialist, Ohio State University, College of Pharmacy
Note: Jujama respects your privacy and assures you that all of your personal contact information will be kept confidential. Rest assured that no contact information will be shared via our platform.
Our full service app allows you to manage your time efficiently and effectively at the event, while ensuring you meet all the right people.
The app will go live 6 weeks before the event. At that time, you will receive an email with your personalised login.
The app is available on desktop as well as the app store.
NETWORKING APPDIRECT MESSAGING / 1-2-1 MEETINGSYou can view and message speakers, sponsors and attendees to set up on site meetings & share content leading up to & at the event. Scheduled meetings will take place in the networking zone at a reserved table.
SOCIAL MEDIABe sure to check out the floorplan to ensure you aren’t missing out on meeting with exhibitors and activities happening on the exhibition floor.
LIVE EVENT NOTIFICATIONS Be sure to check out the floorplan to ensure you aren’t missing out on meeting with exhibitors and activities happening on the exhibition floor.
FLOORPLAN Be sure to check out the floorplan to ensure you aren’t missing out on meeting with exhibitors and activities happening on the exhibition floor.
AGENDAUse the app to view the most up to data agenda & highlight the sessions you want to attend. You can create your own personal schedule!
2 DAY PASS
$2,000
BOOK YOUR PASS BY JULY 12 TO SAVE 50%
Bringing the price to
$1,000
BOOK A GROUP OF 3 OR MORE AND SAVE AN ADDITIONAL 30%
Bringing the price to
$700
REGISTER NOW
Register now at www.terrapinn.com/antimicrobial
PLATINUM SPONSOR
GOLD SPONSOR
SILVER SPONSOR
BRONZE SPONSORS
2019 SPONSORS
Register now at www.terrapinn.com/antimicrobial
